John Evans joined Beam in 2017 as CEO, bringing significant experience as a company builder, dealmaker, and drug developer in the biotechnology industry. Mr. Evans was previously an early employee and member of the leadership team at Agios Pharmaceuticals, most recently serving as Senior Vice President for Corporate Development and Portfolio Leadership. At Agios, Mr. Evans served as IDH Portfolio Executive, providing strategic and operational leadership for a portfolio of first-in-class IDH inhibitors including IDHIFA and TIBSOVO. He helped initiate and lead Agios’ landmark alliance with Celgene, resulting in over $600M of funding and investments across multiple research collaborations in cancer metabolism. He also co-led Agios’s expansion into rare genetic diseases. Prior to joining Agios, Mr. Evans worked at Infinity Pharmaceuticals, McKinsey & Company (Pharmaceuticals practice) and MedImmune.